Corcept Therapeutics Valuation
| CORT Stock | USD 58.60 0.02 0.03% |
At this time, the firm appears to be overvalued. Corcept Therapeutics shows a prevailing Real Value of $48.05 per share. The current price of the firm is $58.6. Our model approximates the value of Corcept Therapeutics from analyzing the firm fundamentals such as Current Valuation of 5.77 B, return on equity of 0.26, and Profit Margin of 0.23 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Corcept Therapeutics' valuation include:
Price Book 9.6077 | Enterprise Value 5.8 B | Enterprise Value Ebitda 39.8889 | Price Sales 9.7681 | Forward PE 32.1543 |
Overvalued
Today
Please note that Corcept Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Corcept Therapeutics is based on 3 months time horizon. Increasing Corcept Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Corcept Therapeutics' intrinsic value may or may not be the same as its current market price of 58.60, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 58.6 | Real 48.05 | Target 34.08 | Hype 57.92 |
The intrinsic value of Corcept Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Corcept Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Corcept Therapeutics Incorporated helps investors to forecast how Corcept stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Corcept Therapeutics more accurately as focusing exclusively on Corcept Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Corcept Therapeutics' intrinsic value based on its ongoing forecasts of Corcept Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Corcept Therapeutics' closest peers.
Corcept Therapeutics Cash |
|
Corcept Valuation Trend
Corcept Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Corcept Therapeutics' financial worth over time. Using both Corcept Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Corcept Therapeutics Total Value Analysis
Corcept Therapeutics Incorporated is currently projected to have valuation of 5.77 B with market capitalization of 6.14 B, debt of 151 K, and cash on hands of 370.09 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Corcept Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.77 B | 6.14 B | 151 K | 370.09 M |
Corcept Therapeutics Investor Information
About 86.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.61. Corcept Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Corcept Therapeutics' liquidity, profitability, solvency, and operating efficiency, Corcept Therapeutics Incorporated is doing better financially today then in previous quarter. It has a moderate probability of reporting better financial numbers in December.Corcept Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Corcept Therapeutics has an asset utilization ratio of 77.61 percent. This implies that the Company is making $0.78 for each dollar of assets. An increasing asset utilization means that Corcept Therapeutics Incorporated is more efficient with each dollar of assets it utilizes for everyday operations.Corcept Therapeutics Ownership Allocation
Corcept Therapeutics holds a total of 104.78 Million outstanding shares. The majority of Corcept Therapeutics Incorporated outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Corcept Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Corcept Therapeutics. Please pay attention to any change in the institutional holdings of Corcept Therapeutics Incorporated as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Corcept Therapeutics Profitability Analysis
The company reported the previous year's revenue of 482.38 M. Net Income was 106.14 M with profit before overhead, payroll, taxes, and interest of 396.47 M.About Corcept Therapeutics Valuation
The stock valuation mechanism determines Corcept Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Corcept Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Corcept Therapeutics. We calculate exposure to Corcept Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Corcept Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 475.9 M | 499.7 M | |
| Pretax Profit Margin | 0.26 | 0.27 | |
| Operating Profit Margin | 0.22 | 0.23 | |
| Net Profit Margin | 0.22 | 0.23 | |
| Gross Profit Margin | 0.99 | 0.78 |
Corcept Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Corcept Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 111.7 M | |
| Quarterly Earnings Growth Y O Y | 0.464 | |
| Forward Price Earnings | 32.1543 |
Corcept Therapeutics Current Valuation Indicators
Corcept Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Corcept Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Corcept Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Corcept Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Corcept Therapeutics' worth.Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.